TxCell Granted €1.7M From Bpifrance to Develop Crohn’s Therapy
Crohn's Disease, News
Biotechnology company TxCell SA has been granted EUR 1.7 million ($1.9 million) from Bpifrance to support the development of the company’s lead product candidate Ovasave (ovalbumin-specific autologous Treg cells). TxCell is working on the ... Read more